News

Registration Now Open for Catalyst Life Sciences Conference

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), announced that registration is open for the Catalyst Life Sciences Conference. The event will be held October 6-7, 2022 at the Omni Hotel in  Richmond, Virginia.

This conference is designed for scientists, engineers, entrepreneurs, incubators and biohubs, life science companies, technology transfer departments and economic development departments. The format consists of expert panels sharing their knowledge and engaging in dialog with the audience.

Joni L. Rutter, Ph.D. will be a keynote speaker. Dr. Rutter is the Acting Director of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). NCATS was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster.

Expert panel topics include: Best Practices for Building a High-Potential Company, Scientists and Engineers as Entrepreneurs, Raising Capital, Establishing and Building Ecosystems, Growing Pharmaceutical Manufacturing and R-D Cluster, and Partnering with Companies and Healthcare Systems. For the full agenda and speakers, visit: https://www.virginiacatalyst.org/agenda.html.

“The Virginia Catalyst and our major Virginia-based research universities, along with Virginia Bio are excited to host a major life sciences conference to share best practices and encourage collaborations. It is through this collaborative ecosystem that we are improving human health and further developing our life science economy by creating innovative companies, capital formation, and job creation,” said Michael Grisham, President & CEO, Virginia Catalyst.

To register: https://www.virginiacatalyst.org/registration.html

Recent News

10/22/2025

Virginia Catalyst Announces Round 19 of Grant Funding

The Virginia Catalyst announced today that it is accepting letters of intent (LOI) for Grant Round 19 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “We at the Virginia Catalyst are pleased to provide funding in support of the Governor’s

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program

10/21/2025

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. The designation follows previously granted Orphan